
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably due to its promising development of stenoparib, which has demonstrated a median overall survival exceeding 25 months in its Phase 2 trial for patients with advanced recurrent ovarian cancer. The company's proprietary Drug Response Predictor (DRP) technology enhances patient selection, which is expected to improve clinical outcomes and address significant unmet medical needs in oncology. Furthermore, the consistent upward adjustment in 12-month price targets—indicative of a positive net present value (NPV) analysis—highlights the attractive valuation of the company amidst its ongoing clinical advancements.
Bears say
Allarity Therapeutics has reported a net loss of $2.8 million, resulting in an earnings per share (EPS) of $(0.19), which indicates financial performance that fell short of prior estimates. The company's balance sheet presents significant liquidity risks, exacerbated by the ongoing uncertainty regarding the safety and efficacy of its product candidates, specifically stenoparib, in clinical trials and regulatory approvals. Furthermore, a multitude of external factors, such as evolving investor sentiment towards biotechnology stocks and potential challenges in commercialization and reimbursement, compounds the negative outlook for Allarity Therapeutics's stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares